डेफेरासिरोक्स और ऑर्फेनाड्रिन, एस्पिरिन और कैफीन का इंटरैक्शन

Avoid the use of Exjade with CYP1A2 substrate theophylline.

Avoid the concomitant use of theophylline or other CYP1A2 substrates with a narrow therapeutic index (e.g., tizanidine) with Exjade.

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants.

Agents Metabolized by CYP1A2 Deferasirox inhibits CYP1A2 resulting in an increase in CYP1A2 substrate (e.g., alosetron, caffeine, duloxetine, melatonin, ramelteon, tacrine, theophylline, tizanidine) concentration when these drugs are coadministered.

An increase in theophylline plasma concentrations could lead to clinically significant theophylline-induced CNS or other adverse reactions.